Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 04, 2019
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study.
Journal: British journal of haematology
Published: September 22, 2016
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.
Journal: Leukemia & lymphoma
Published: February 20, 2016
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 27, 2015
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Journal: Haematologica
Published: January 18, 2015
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
Journal: British journal of haematology
Published: November 10, 2014
Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression.
Journal: Blood cancer journal
Published: August 09, 2014
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Journal: British journal of haematology
Published: March 19, 2014
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
Journal: Leukemia & lymphoma
Published: December 27, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 02, 2013
SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.
Journal: Cell death & disease
Published: May 18, 2013
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
Journal: Leukemia research
Published: April 05, 2013
Last Updated: 09/26/2026